Neurology
Testing developed by neurologists, for neurologists
Through our integration with Mayo Clinic, Mayo Clinic Laboratories leads the industry in turning test results into clinical answers. Neurology testing is rapidly evolving, with increasing numbers of clinically relevant biomarkers discovered each year. Mayo Clinic Laboratories collaborates closely with the practice and is designed to offer the most complex, clinically validated testing. Our disease experts support health care professionals in test selection and results interpretation to ensure proper test utilization and the highest quality of care.
Highlights
Autoimmune neurology testing has evolved beyond limited paraneoplastic evaluations to phenotype-specific panels that identify clinically relevant antibodies. This phenotype-specific approach significantly improves diagnostic accuracy, reduces false positives, and helps guide faster, more personalized treatment for complex neurological diseases.
Learn more about how our movement disorders testing can help diagnose testicular cancer-associated paraneoplastic encephalitis.
Learn more about how our testing protocol is useful in the diagnosis of sorbitol dehydrogenase (SORD) deficiency.
Find out how we use glycine receptor Ab as a marker of stiff-person syndrome spectrum disorder.
Learn more about the risks of false positives with AQP4 ELISA methodology in CNS demyelinating disease testing.
Learn how a phenotype-specific autoimmune neurology evaluation diagnosed a treatable autoimmune encephalitis condition that was missed with a traditional paraneoplastic evaluation.
Find out how our testing uses neurofascin 155 IgG4 antibodies as a specific marker of chronic inflammatory demyelinating polyradiculoneuropathy.
Learn more about our CNS demyelinating disease testing through this case study focused on MOG-IgG as a marker of acute disseminated encephalomyelitis.
This webinar will discuss how autoimmune neurology testing has changed with expanding antibody discovery and why a patient-first, phenotype-specific approach improves test selection and interpretation.
Mayo Clinic Laboratories’ MS testing cascade, which starts with kappa free light chain (KFLC) testing and reflexes to oligoclonal banding when indicated, is supported by the revised 2024 McDonald Criteria. This approach delivers faster, more definitive results, enabling earlier treatment decisions and improved patient outcomes.
In this presentation, Eoin Flanagan, M.B., B.Ch., a leading specialist in neuroimmunology at Mayo Clinic, provides a clear and clinically focused overview of autoimmune conditions that affect the developing nervous system.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to explore recent examples of diagnostic innovations that are improving patient care. Dr. Pritt also welcomes Matthew Schultz, Ph.D., a clinical biochemical geneticist at Mayo Clinic, to discuss how a novel test is delivering answers for patients with a recently identified peripheral neuropathy.